Literature DB >> 9657272

Protein kinase C: a potential pathway of macrophage activation with cisplatin.

S Shishodia1, A Shrivastava, A Sodhi.   

Abstract

Cisplatin (CP) has been reported to activate murine macrophages to tumoricidal state, however, its mechanism of action is not known. In the present study it is reported that the production of: (a) interleukin-1 (IL-1); (b) tumor necrosis factor (TNF); (c) nitric oxide (NO); and (d) macrophage-mediated cytotoxicity by cisplatin-treated bone marrow-derived macrophages were inhibited by PKC inhibitors H-7 and chelerythrine chloride. Also, it was observed that treatment of macrophages with CP resulted in the translocation of PKC from the cytosol to the membrane fraction. These findings suggest the involvement of PKC in the activation of bone marrow-derived macrophages with cisplatin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657272     DOI: 10.1016/s0165-2478(98)00017-0

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity.

Authors:  Collin R Elsea; Daniel A Roberts; Brian J Druker; Lisa J Wood
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

2.  Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.

Authors:  Woo Sik Kim; Hongmin Kim; Kee Woong Kwon; Sin-Hyeog Im; Bo Ryeong Lee; Sang-Jun Ha; Sung Jae Shin
Journal:  Oncotarget       Date:  2016-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.